Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination

Livramento, Andréa do; Schultz, Júnia; Batista, Keila Zaniboni Siqueira; Treitinger, Arício; Córdova, Caio Maurício Mendes de; Spada, Celso

doi:10.1002/jmv.24012

Cited by 10 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decline of anti-HBs with the progress of age among vaccinated individuals has been repeatedly reported [27][28][29]. Such individuals have been demonstrated to have immunological memory that developed after primary immunization [30,31]. This immunological memory could still be boosted by natural exposure, which may explain the low HBV infection rate among our donors.…”

Section: Discussionmentioning

confidence: 69%

Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in Al-Baha, Saudi Arabia

Almutairi

AlAhmari²,

Al-Zahran³

et al. 2016

J Infect Dev Ctries

View full text Add to dashboard Cite

Introduction: Data on blood-borne viral infections in some regions in Saudi Arabia remain scarce. This study investigates the prevalence of serological markers and nucleic acid for blood-borne viruses among blood donors in Al-Baha, Kingdom of Saudi Arabia. Methodology: In this cross-sectional study, 2,807 donors who donated blood between January 2009 and November 2011 were investigated for blood-borne viral serological markers including HBsAg, anti-HBc, anti-HBs, anti-HCV, anti-HIV, and anti-HTLVI/III in addition to viral nucleic acid. Results: All donors were males between 16 to 66 years of age (mean: 31.5 ± 9.3 years). Viral nucleic acid and/or serological markers were detected in a total of 36 (1.3%) donors; of them, 26 (72.2%) had nucleic acid concomitant with serological markers, 6 (16.7%) had only viral nucleic acid, while 4 (11.1%) had only serological markers. Of all donors, 22 (0.8%) had HBsAg, 227 (8.0%) had anti-HBc, 157 (5.0%) had anti-HBs, 2,577 (91.8%) had no HBV markers, 2 (0.07%) had anti-HIV, 1 (0.04%) had anti-HCV, and 1 (0.04%) had anti-HTLVI/II. The donors who were born during HBV vaccination era showed no HBsAg (0.0%; p = 0.052), lower rates of anti-HBc (1.5%; p < 0.001) and antiHBs (0.7%; p < 0.001), while the majority had no HBV markers (98.5%; p < 0.001). Conclusions: Combined viral nucleic acid and serological testing of donated blood enhances blood safety. The absence of HBV markers among donors suggests susceptibility or declined anti-HBs levels. Thus, HBV revaccination or a vaccine boost among adolescents and adults might be indispensable.

show abstract

Section: Discussionmentioning

confidence: 69%

Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in Al-Baha, Saudi Arabia

Almutairi

AlAhmari²,

Al-Zahran³

et al. 2016

J Infect Dev Ctries

View full text Add to dashboard Cite

show abstract

“…Previous results showed that memory T cells maintain the response to the virus after encountering. This issue has been highlighted by the fact that after booster dose(s) of HBV vaccine in hypo/nonresponders, there has been amnestic response manifested by increase in the levels of anti-HBs (45,51).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study

et al. 2015

View full text Add to dashboard Cite

Context: Hepatitis B Virus expanded program on immunization (EPI) started on 1993 in Iran. Most surveys have assessed the level of response to vaccine by measuring the titers of anti-HBs. This meta-analysis aimed to summarize the Iranian published data on the rate of vaccine-responders versus non-responders. Moreover, the impact of variables such as age, gender, type of vaccine, etc. on the levels of responsiveness was evaluated. Evidence Acquisition: All published papers on this topic in Iranian and international journals with affiliation of "Iran" were reviewed using standard keywords up to 2014. We included our study to healthy participants with no previous HBV infection and who had already received a complete course of HB vaccine. The estimated prevalence and 95% confidence intervals in 28 eligible articles for HBV vaccine responders (anti-HBs > 10 IU/mL) and non-responders (10 <) were analyzed by random effect method due to between-study heterogeneity. Results: The age of subjects was between 6 months and 15 years old. Overall, 5991 (51.5%) were male and 4571 (48.5%) females. Overall, 80% were responders to vaccine versus 20% nonresponders. With increase in age, the number of responders to vaccine decreased significantly (P = 0.001). There was no strong difference between responders versus nonresponders to vaccine for gender, types of vaccine, ethnicity and living area. Conclusions:The results arose from this meta-analysis highlighted the safety of vaccine and its effectiveness in stimulating immune response of vaccines, despite being different in generation, manufacturers and types. Moreover, there was no substantial difference between Iranian and other international investigations in the rate of nonresponsiveness to HBV vaccine.

show abstract

“…Some recent studies indicated disappearance of immune memory in a significant number of vaccinees, most of whom showed a good initial response to primary course of vaccination ( 21 , 22 ). Several studies aimed to detect and measure the HBV surface antigen (HBsAg)-specific T-cells and B-cells reactivity in vaccinees to show the presence of specific immune memory; however, the results were contradictory ( 10 , 21 - 26 ). this study aimed to determine whether the HBs Ag-specific T-cell memory could persist for a long period of time after neonatal HB vaccination, particularly in vaccine recipients whose serum antibodies levels against HBsAg (HBsAb) was less than protective (< 10 IU/L) to make an optimal policy of booster vaccination.…”

Section: Introductionmentioning

confidence: 99%

Long-Term T-Cell-Mediated Immunologic Memory to Hepatitis B Vaccine in Young Adults Following Neonatal Vaccination.

Saffar

Ajami

et al. 2014

Hepat Mon

View full text Add to dashboard Cite

Background:The long-term duration of cell-mediated immunity induced by neonatal hepatitis B virus (HBV) vaccination is unknown.Objectives:Study was designed to determine the cellular immunity memory status among young adults twenty years after infantile HB immunization.Patients and Methods:Study subjects were party selected from a recent seroepidemiologic study in young adults, who had been vaccinated against HBV twenty years earlier. Just before and ten to 14 days after one dose of HBV vaccine booster injection, blood samples were obtained and sera concentration of cytokines (interleukin 2 and interferon) was measured. More than twofold increase after boosting was considered positive immune response. With regard to the serum level of antibody against HBV surface antigen (HBsAb) before boosting, the subjects were divided into four groups as follow: GI, HBsAb titer < 2; GII, titer 2 to 9.9; GIII, titer 10 to 99; and GIV, titers ≥ 100 IU/L. Mean concentration level (MCL) of each cytokines for each group at preboosting and postboosting and the proportion of responders in each groups were determined. Paired descriptive statistical analysis method (t test) was used to compare the MCL of each cytokines in each and between groups and the frequency of responders in each group.Results:Before boosting, among 176 boosted individuals, 75 (42.6%) had HBsAb 10 IU/L and were considered seroprotected. Among 101 serosusceptible persons, more than 80% of boosted individuals showed more than twofold increase in cytokines concentration, which meant positive HBsAg-specific cell-mediated immunity. MCL of both cytokines after boosting in GIV were decreased more than twofold, possibly because of recent natural boosting.Conclusions:Findings showed that neonatal HBV immunization was efficacious in inducing long-term immunity and cell-mediated immune memory for up to two decades, and booster vaccination are not required. Further monitoring of vaccinated subjects for HBV infections are recommended.

show abstract

Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination

Cited by 10 publications

References 29 publications

Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in Al-Baha, Saudi Arabia

Prevalence of serological markers and nucleic acid for blood-borne viral infections in blood donors in Al-Baha, Saudi Arabia

Prevalence of National Responsiveness to HBV Vaccine After 22 Years of Iranian Expanded Program on Immunization (EPI): A Systematic Review and Meta-Analysis Study

Long-Term T-Cell-Mediated Immunologic Memory to Hepatitis B Vaccine in Young Adults Following Neonatal Vaccination.

Contact Info

Product

Resources

About